102 related articles for article (PubMed ID: 17822885)
21. Relationship between neuroleptic extrapyramidal syndromes and patients' all-cause mortality.
Modestin J; Vogt Wehrli M; Stephan PL; Agarwalla P
Pharmacopsychiatry; 2009 Mar; 42(2):57-60. PubMed ID: 19308879
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of melatonin in tardive dyskinesia.
Castro F; Carrizo E; Prieto de Rincón D; Rincón CA; Asián T; Medina-Leendertz S; Bonilla E
Invest Clin; 2011 Sep; 52(3):252-60. PubMed ID: 21950196
[TBL] [Abstract][Full Text] [Related]
23. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study.
Wilting I; Heerdink ER; Mersch PP; den Boer JA; Egberts AC; Nolen WA
Bipolar Disord; 2009 Jun; 11(4):434-40. PubMed ID: 19500096
[TBL] [Abstract][Full Text] [Related]
24. Tardive dyskinesia and glucid metabolism.
Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
[TBL] [Abstract][Full Text] [Related]
25. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
[TBL] [Abstract][Full Text] [Related]
26. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients.
Kang SG; Choi JE; An H; Park YM; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Joe SH; Jung IK; Kim L; Lee MS
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1844-7. PubMed ID: 18790709
[TBL] [Abstract][Full Text] [Related]
27. Treating a schizophrenic patient with severe tardive dystonia without antipsychotics.
Suzuki T; Uchida H; Watanabe K; Kashima H
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1141-2. PubMed ID: 17481792
[No Abstract] [Full Text] [Related]
28. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation.
Kefalopoulou Z; Paschali A; Markaki E; Vassilakos P; Ellul J; Constantoyannis C
Acta Neurol Scand; 2009 Apr; 119(4):269-73. PubMed ID: 18976318
[TBL] [Abstract][Full Text] [Related]
29. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
Kenney C; Hunter C; Jankovic J
Mov Disord; 2007 Jan; 22(2):193-7. PubMed ID: 17133512
[TBL] [Abstract][Full Text] [Related]
30. [Follow-up of patients that use lithium].
Solberg DK; Refsum H
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1410-2. PubMed ID: 18552904
[TBL] [Abstract][Full Text] [Related]
31. The association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia.
Schultz SK; Ellingrod V; Fleming FW; Andreasen NC
Hum Psychopharmacol; 2001 Apr; 16(3):273-277. PubMed ID: 12404580
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of pallidal deep brain stimulation in tardive dystonia.
Gruber D; Trottenberg T; Kivi A; Schoenecker T; Kopp UA; Hoffmann KT; Schneider GH; Kühn AA; Kupsch A
Neurology; 2009 Jul; 73(1):53-8. PubMed ID: 19564584
[TBL] [Abstract][Full Text] [Related]
33. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study.
Severus WE; Kleindienst N; Evoniuk G; Bowden C; Möller HJ; Bohus M; Frangou S; Greil W; Calabrese JR
J Affect Disord; 2009 Jun; 115(3):466-70. PubMed ID: 19019453
[TBL] [Abstract][Full Text] [Related]
34. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
35. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM).
Vieta E; Angst J; Reed C; Bertsch J; Haro JM;
J Affect Disord; 2009 Nov; 118(1-3):118-23. PubMed ID: 19269690
[TBL] [Abstract][Full Text] [Related]
36. Tardive dyskinesia rating scales.
Simpson GM; Singh H
Encephale; 1988 Sep; 14 Spec No():175-82. PubMed ID: 3063512
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel.
Lerner V; Libov I; Kaptsan A; Miodownik C; Dwolatzky T; Levine J
Isr J Psychiatry Relat Sci; 2007; 44(1):20-8. PubMed ID: 17665807
[TBL] [Abstract][Full Text] [Related]
38. Treatment of tardive dyskinesia with levetiracetam in a transplant patient.
Zivković SA; Costa G; Bond G; Abu-Elmagd KM
Acta Neurol Scand; 2008 May; 117(5):351-3. PubMed ID: 17995990
[TBL] [Abstract][Full Text] [Related]
39. [Dementia following bipolar disorder].
Lebert F; Lys H; Haëm E; Pasquier F
Encephale; 2008 Dec; 34(6):606-10. PubMed ID: 19081458
[TBL] [Abstract][Full Text] [Related]
40. Reliability, validity, and a total score cutoff for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations.
Sprague RL; Kalachnik JE
Psychopharmacol Bull; 1991; 27(1):51-8. PubMed ID: 1862206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
